NEW DELHI: Biocon Ltd on Thursday announced the inauguration of its first manufacturing facility in the United States, located in Cranbury, New Jersey. The plant is operated by the company’s wholly-owned subsidiary, Biocon Generics Inc. (BGI).
Biocon had acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over USD 30 million to establish a plant with an annual production capacity of 2 billion tablets. Several products have already been commercialized from the site, with more in the pipeline, the Bengaluru-based company said in a statement.
The investment is aimed at diversifying Biocon’s manufacturing base, strengthening its supply chain, and accelerating the growth of its global footprint.
“Biocon’s first USFDA-approved formulations facility in New Jersey marks a significant milestone in our journey of global expansion,” said Kiran Mazumdar-Shaw, Chairperson of Biocon Group. “The facility underscores our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and more equitable future.”
